They demonstrated that antigen-specific CD8+ T-cells from mice immunised with the optimised construct expressed higher PD-1 and, partly in line with our observations, anti-tumour activity of the optimised vaccine increased when combined with PD-1 or PD-L1 blocking antibodies. Here, CD8A is linked to neoplasm.